Product Description: Eflornithine hydrochloride hydrate (DFMO hydrochloride hydrate) is a specific, irreversible inhibitor of the enzyme ornithine decarboxylase. Eflornithine hydrochloride hydrate is a medication for the treatment of African trypanosomiasis and excessive facial hair growth in women[1].
Applications: Cancer-programmed cell death
Formula: C6H15ClF2N2O3
Citations: Cell Rep. 2025 Jan 28;44(1):115123./Front Oncol. 2021 Mar 11;11:636373./Sci Adv. 2023 May 19;9(20):eade0718./bioRxiv. 2024 Jan 15./Cancer Nanotechnol. 2023 May 9./Cell Rep. 2025 Feb 28;44(3):115370./Commun Biol. 2019 May 8;2:171./Food Biosci. 2023 Oct, 55, 102970./JACC Basic Transl Sci. 2022 Aug 3;7(8):820-840./Nat Commun. 2024 Mar 19;15(1):2461./Oncotargets Ther. 2020 Nov 17;13:11697-11709./RSC Adv. 2019, 9, 11026-11037.
References: [1]Burri C, et al. Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res. 2003 Jun;90 Supp 1:S49-52./[2]Balfour JA, et al. Topical eflornithine. Am J Clin Dermatol. 2001;2(3):197-201; discussion 202./[3]Kumar A, et al. A method to improve the efficacy of topical eflornithine hydrochloride cream. Drug Deliv. 2016 Jun;23(5):1495-501./[4]Lipke DW, et al. Eflornithine alters changes in vascular responsiveness associated with coarctation hypertension. Clin Exp Hypertens. 1997 Apr;19(3):297-312.
CAS Number: 96020-91-6
Molecular Weight: 236.64
Compound Purity: 98.0
Research Area: Cancer
Solubility: H2O : 83.33 mg/mL (ultrasonic)
Target: Parasite
Deutsch
English
